<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1621">
  <stage>Registered</stage>
  <submitdate>10/07/2007</submitdate>
  <approvaldate>10/07/2007</approvaldate>
  <nctid>NCT00499850</nctid>
  <trial_identification>
    <studytitle>Phase I FOLFOX Combination</studytitle>
    <scientifictitle>A Phase I,Open Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as First and Second Line Therapy in Patients With Advanced Colorectal Adenocarcinoma.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>D4200C00037</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Colorectal Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ZD6474 (vandetanib)
Treatment: drugs - 5-Fluorouracil
Treatment: drugs - Leucovorin
Treatment: drugs - Oxaliplatin

Treatment: drugs: ZD6474 (vandetanib)
once daily oral dose

Treatment: drugs: 5-Fluorouracil
intravenous infusion

Treatment: drugs: Leucovorin
intravenous infusion

Treatment: drugs: Oxaliplatin
intravenous infusion

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin</outcome>
      <timepoint>Assessed at each visit</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Histologically confirmed locally advanced, recurrent or metastatic colorectal
             adenocarcinoma (Stage IV)

          2. WHO performance status 0-1

          3. one or more measurable lesions min 10mm by spiral CT or min 20mm by conventional
             techniques</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Brain metastasis or spinal cord compression unless irradiated at least 4 weeks before
             entry and stable

          2. last dose of prior chemotherapy discontinued at least 4 weeks before start study
             treatment

          3. prior unanticipated severe reaction to oxaliplatin</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>18</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - East Melbourne</hospital>
    <hospital>Research Site - Footscray</hospital>
    <hospital>Research Site - Heidelberg</hospital>
    <hospital>Research Site - Parkville</hospital>
    <postcode> - East Melbourne</postcode>
    <postcode> - Footscray</postcode>
    <postcode> - Heidelberg</postcode>
    <postcode> - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genzyme, a Sanofi Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase I,open label study to assess the safety and tolerability of ZD6474 in combination
      with 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as first and second line therapy
      in patients with advanced colorectal adenocarcinoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00499850</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Sciences &amp; Operations</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>